Home > Healthcare & Medical Devices > In-Vitro Toxicology Testing Market
In-vitro Toxicology Testing Market size was valued at around USD 10 billion in 2022 and is expected to rise at a 10-12% CAGR from 2023 to 2032.
In-vitro toxicology is a process of evaluating hazardous compounds present on isolated organisms. It is used in the initial phases of production to detect toxic drugs and determine toxicity in new pharmaceuticals, cosmetics, and food products. The latest advancements in physiologically realistic in-vitro model systems show promise for improving the translation of test results to forecast detrimental effects in humans.
The rising demand for 3D in-vitro models in toxicology research is a major factor driving the in-vitro toxicology testing market trends. 3D in-vitro models are commonly utilized as they may contain various patient-derived tissues/cells, allowing for continuous readouts and enabling in-depth analysis of cell interactions.
Based on technology, the cell culture segment is set to hold a large market share in 2023. Recent advancements in human cell culture exposure and test methods have enabled the extension & development of in-vitro assay systems that are predictive, demonstrative, and ideal for toxicity screening of numerous chemicals including nanomaterials and airborne contaminants. Cell culture techniques also enable initial-stage drug toxicity assessment, thereby gaining popularity. It is used in the place of animal testing by healthcare academic institutions, biotechnology companies, and pharmaceutical manufacturers worldwide.
In-vitro toxicology testing market from dermal toxicity segment will experience significant gains throughout the forecast years. In-vitro toxicology tests for determining skin toxicity are simpler, more cost-effective, and more reliable than animal testing. The regulations for toxicity assessment of cosmetics are also driving the progress for in-vitro dermal toxicity testing. The restrictions on animal testing of cosmetic ingredients and products have prompted the cosmetics industry to develop innovative non-animal techniques. The pharmaceutical industry is developing & employing novel in-vitro techniques and in-silico technologies (using machine learning and artificial intelligence), which show more promise than animal models in predicting human responses.
The prominent players in the in-vitro toxicology testing industry are Charles River Laboratories International, Inc., SGS S.A., Merck KGaA, Eurofins Scientific, Abbott Laboratories, Laboratory Corporation of America Holdings, Evotec S.E., Thermo Fisher Scientific, Inc., Quest Diagnostics Incorporated, Agilent Technologies, Inc., Catalent, Inc., Danaher Corporation, and Bio-Rad Laboratories, Inc.